Fassunke, Jana

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Scheffler, M., Ihle, M. A., Hein, R., Merkelbach-Bruse, S., Scheel, A. H., Siemanowski, J., Brägelmann, J., Kron, A., Abedpour, N., Ueckeroth, F., et al. (2019) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 264

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., et al. (2018) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 197

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

Scheffler, M., Bos, M., Gardizi, M., König, K., Michels, S., Fassunke, J., Heydt, C., Künstlinger, H., Ihle, M., Ueckeroth, F., et al. (2015) · Oncotarget

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 147

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

Michels, S., Scheel, A. H., Scheffler, M., Schultheis, A. M., Gautschi, O., Aebersold, F., Diebold, J., Pall, G., Rothschild, S., Bubendorf, L., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 91

Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations

Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A. H., Frank, S., Holz, B., et al. (2018) · The Journal of Pathology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 69